Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefan Ruepp

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
ACS Medicinal Chemistry Letters|August 20, 2015
Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative NeoplasmsHonghe Wan, Gretchen M Schroeder, Amy C Hart, et al.
Cancer Research|September 24, 2025
PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated CancersMichael Hulse, Min Wang, Chaoyi Xu, et al.
ACS Medicinal Chemistry Letters|July 18, 2020
Optimization of Nicotinamides as Potent and Selective IRAK4 Inhibitors with Efficacy in a Murine Model of PsoriasisSatheesh Nair, Sreekantha Ratna Kumar, Venkatram Reddy Paidi, et al.
Journal of Medicinal Chemistry|May 26, 2017
Identification of a Potent, Selective, and Efficacious Phosphatidylinositol 3-Kinase δ (PI3Kδ) Inhibitor for the Treatment of Immunological DisordersQingjie Liu, Qing Shi, David Marcoux, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
ACS Medicinal Chemistry Letters|August 20, 2015
Discovery of a Highly Selective JAK2 Inhibitor, BMS-911543, for the Treatment of Myeloproliferative NeoplasmsHonghe Wan, Gretchen M Schroeder, Amy C Hart, et al.
Cancer Research|September 24, 2025
PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated CancersMichael Hulse, Min Wang, Chaoyi Xu, et al.
ACS Medicinal Chemistry Letters|July 18, 2020
Optimization of Nicotinamides as Potent and Selective IRAK4 Inhibitors with Efficacy in a Murine Model of PsoriasisSatheesh Nair, Sreekantha Ratna Kumar, Venkatram Reddy Paidi, et al.
Journal of Medicinal Chemistry|May 26, 2017
Identification of a Potent, Selective, and Efficacious Phosphatidylinositol 3-Kinase δ (PI3Kδ) Inhibitor for the Treatment of Immunological DisordersQingjie Liu, Qing Shi, David Marcoux, et al.
Pageof 2